Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

A Coefficient of Agreement for Nominal Scales

Cohen, J. (1960) · Educational and Psychological Measurement · doi:10.1177/001316446002000104 · Cited by 42,398

Statistical Methods for Rates and Proportions

Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005

Fleiss, J. L.: Statistical Methods for Rates and Proportions. John Wiley & Sons, New York‐London‐Sydney‐Toronto 1973. XIII, 233 S.

Toutenburg, H. (1974) · Biometrische Zeitschrift · doi:10.1002/bimj.19740160814 · Cited by 1,547

The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study

Sprangers, M. A., Groenvold, M., Arraras, J. I., Franklin, J., te Velde, A., Muller, M., Franzini, L., Williams, A., de Haes, H. C., Hopwood, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2756 · Cited by 1,220

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials

Bergman, B., Aaronson, N. K., Ahmedzai, S. H., Kaasa, S., & Sullivan, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90535-5 · Cited by 906

Patient versus clinician symptom reporting using the national cancer institute common terminology criteria for adverse events: results of a questionnaire-based study

Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M. G., Scher, H. I., & Schrag, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70910-x · Cited by 653

How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30

Fromme, E. K., Eilers, K. M., Mori, M., Hsieh, Y.-C., & Beer, T. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.025 · Cited by 555

Physicians' and patients' choices in evidence based practice

Haynes, R. B., Devereaux, P. J., & Guyatt, G. H. (2002) · BMJ · doi:10.1136/bmj.324.7350.1350 · Cited by 534

Correlation of patient and caregiver ratings of cancer pain

Grossman, S. A., Sheidler, V. R., Swedeen, K., Mucenski, J. W., & Piantadosi, S. (1991) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(91)90518-9 · Cited by 434

Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer

Killingberg, K. T., Halvorsen, T. O., Fløtten, Ø., Brustugun, O. T., Langer, S. W., Nyman, J., Hornslien, K., Madebo, T., Schytte, T., Risum, S., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.02.002 · Cited by 5

Patient-reported outcomes version of the common terminology criteria for adverse events and quality-of-life linear analogue self-assessment in breast cancer patients receiving radiation therapy: single-institution prospective registry

Thorpe, C. S., DeWees, T. A., Golafshar, M. A., Bhangoo, R. S., Vern-Gross, T. Z., McGee, L. A., Wong, W. W., Halyard, M. Y., Keole, S. R., & Vargas, C. (2022) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-021-00408-9 · Cited by 7

Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy

Korver, S. K., Bowen, J. M., Gibson, R. J., Ball, I. A., Secombe, K. R., Wain, T. J., Logan, R. M., Tuke, J., Mead, K. R., Richards, A. M., et al. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04538-3 · Cited by 6

The use of electronic Patient Reported Outcomes in follow-up after palliative radiotherapy: A survey study in Belgium

Oldenburger, E., Isebaert, S. F., Coolbrandt, A., Audenhove, C. V., & Haustermans, K. M. (2023) · PEC Innovation · doi:10.1016/j.pecinn.2023.100243 · Cited by 6

Survey on symptoms in patients receiving chemotherapy in an Italian department of oncology: a comparison between period prevalences

Crivelli, F., Perfetti, E., Sartorello, B., Cantele, V., Ostano, P., Ilardi, F., Massimo, D. S. D., & Clerico, M. A. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05486-x · Cited by 6

What Is the Role of Symptom Management and Patient-Reported Outcomes in Adherence to Aromatase Inhibitors?

Rocque, G. B. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.3250 · Cited by 6

Importance of patient-reported outcomes and health-related quality of life when considering prostate cancer treatment

Tsu, J. H. (2020) · Hong Kong Medical Journal · doi:10.12809/hkmj205095 · Cited by 6

Effects of an Electronic Patient Reported Outcome Measures (e‐PROMs) Program on Symptom Reporting, Use of Healthcare, and Overall Survival in Patients With Lymphoma: A Multicenter Prospective Study

Córdoba, R., Rodríguez, M. D. O., Ramos-Cillán, S., García, A. L., Morillo, D., Perez-Saenz, M. A., Miranda, C., Martos, R., Beltrán, L., Castillo, E., et al. (2025) · eJHaem · doi:10.1002/jha2.70129 · Cited by 5

Digital illiteracy and access to remote patient monitoring in oncology: a multicentre study of healthcare providers' perceptions and patient-reported digital literacy

Prospero, E., Yazigi, A., Rouzier, R., Franzoi, M. A., & L'Orphelin, J.-M. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103866 · Cited by 7

Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial “GIVE ME FIVE”

Marvaso, G., Corrao, G., Repetti, I., Lorubbio, C., Bellerba, F., Zaffaroni, M., Vincini, M. G., Zerini, D., Alessi, S., Luzzago, S., et al. (2024) · World Journal of Urology · doi:10.1007/s00345-024-04876-8 · Cited by 5

Representativeness and adverse event reporting in late-phase clinical trials for rifampin-susceptible tuberculosis: a systematic review

Burman, W. J., Luczynski, P., Horsburgh, C. R., Phillips, P. P. J., & Johnston, J. C. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00597-8 · Cited by 5

Graphical user interface design to improve understanding of the patient-reported outcome symptom response

Lee, M., Kang, D., Joi, Y. R., Yoon, J., Kim, Y., Kim, J., Kang, M., Oh, D., Shin, S.-Y., & Cho, J. (2023) · PLoS ONE · doi:10.1371/journal.pone.0278465 · Cited by 5

Breast-cancer specific comprehensive archive of Patient-Reported Outcome Measures (PROMs) for clinical research and clinical practice in oncology: Results from the PRO4All project

Valsecchi, A. A., Giovanardi, F., Malandrini, F. B., Meregaglia, M., Servetto, A., Bennati, C., Pinto, C., Maïo, M. D., & Ciani, O. (2024) · The Breast · doi:10.1016/j.breast.2024.103817 · Cited by 5

A cluster-randomised, controlled proof-of-concept study to explore the feasibility and effect of a patient-directed intervention on quality of life in patients with advanced soft tissue sarcoma

Schuler, M. K., Richter, S., Ehninger, G., Bornhäuser, M., & Hentschel, L. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-014614 · Cited by 5

The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY)

Tanioka, H., Nagasaka, T., Uno, F., Inoue, M., Okita, H., Katata, Y., Kanzaki, H., Kuramochi, H., Satake, H., Shindo, Y., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6163-6 · Cited by 5

Reliability of patient-reported toxicities during adjuvant chemotherapy

Cremante, M., Pastorino, A., Ponzano, M., Grassi, M., Martelli, V., Puccini, A., Catalano, F., Murianni, V., Iaia, M. L., Puglisi, S., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.01.005 · Cited by 5

The perception gap of chemotherapy-induced adverse events between doctors and cancer patients: an observational study in China

Yu, J., Zhang, Z., Zhou, H., Liu, X., Huang, Y., Fang, W., Yang, Y., Hong, S., Zhou, T., Zhang, Y., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05649-w · Cited by 5

Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain

Escobar, Y., de Castro, J., Bell, D., Drago, A., & Franceschetti, A. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02623-8 · Cited by 5

The importance of patient-reported outcomes in pragmatic clinical trials

Jim, H., Brady‐Nicholls, R., & Hershman, D. L. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad037 · Cited by 5

Covalent conjugate based on graphene oxide and alkylating agent belonging to 1,3,5-triazine class as promising agent for anticancer chemo- and phototherapy

Semenov, K. N., Сергеевна, Ш. О., Mikolaichuk, O. V., Murin, I. V., Iurev, G. O., Ageev, S. V., Гришачева, Т. Г., Rumiantsev, A. M., Andoskin, P. A., Maistrenko, D. N., et al. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.141046 · Cited by 4

Survival, quality of life, and motor function in brain metastases surgery: The role of complete resection

Winther, R. R., Hjermstad, M. J., Yri, O. E., Skovlund, E., Aass, N., Astrup, G. L., Kaasa, S., Saxhaug, C., & Vik-Mo, E. O. (2025) · Neuro-Oncology Practice · doi:10.1093/nop/npaf011 · Cited by 4

Neurosurgical nurses’ perspectives of patient-reported outcomes: a qualitative study

Han, Y., Wang, Y., Liu, Y., Wang, Z., Dong, X., & Fang, K. (2025) · BMC Nursing · doi:10.1186/s12912-025-03726-1 · Cited by 4

Reliability and validity of the simplified Chinese version of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator

Meng, X., Shang, M., Wang, Q., Yan, R., Jiang, K., Xiang, J., Liu, W., Li, J., Wang, D., & Xu, J. (2022) · Quality of Life Research · doi:10.1007/s11136-022-03318-5 · Cited by 4

Patient‐reported outcomes in immunotherapy for head and neck cancer

Kirtane, K., Hoogland, A. I., Li, X., Rodriguez, Y., Scheel, K. L., Small, B. J., Oswald, L. B., Muzaffar, J., Kish, J. A., Bonomi, M. R., et al. (2023) · Head & Neck · doi:10.1002/hed.27388 · Cited by 4

PRO-CTCAE reveals under-recognition of dermatologic symptom burden in hospitalized cancer patients

Gu, S., Menzer, C., Hay, J. L., Peña, C., Dusza, S. W., Lacouture, M. E., & Markova, A. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-07793-5 · Cited by 4

Systematic review of adoption, reporting and impact of health-related quality of life in phase III non-inferiority trials of systemic oncology treatments

Notarnicola, S., Zumstein, L., Paparo, J., Marandino, L., Perrone, F., & Maïo, M. D. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113374 · Cited by 4

Effect of Communication Mode on Disclosure of Nutrition Impact Symptoms During Nutrition Intervention Delivered to People With Upper Gastrointestinal Cancer

Furness, K., Huggins, C. E., Hanna, L., Croagh, D. G., Sarkies, M., & Haines, T. P. (2024) · Evaluation & the Health Professions · doi:10.1177/01632787241267051 · Cited by 4

Benchmarks of success in radiotherapy vs systemic therapy: National Clinical Trials Network (NCTN) randomized controlled trials sponsored by the National Cancer Institute (NCI)

Sanford, N. N., Shi, Q., Hein, D., & Hall, W. A. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae313 · Cited by 4

Incidence and management of diarrhoea associated with abemaciclib and endocrine therapy for hormone-receptor positive, HER2-negative metastatic breast cancer: the UK patients’ experiences

Harder, H., Starkings, R., Fallowfield, L. J., May, S. F., & Shilling, V. M. (2025) · Supportive Care in Cancer · doi:10.1007/s00520-025-09440-7 · Cited by 4

Quality of Life in Patients with NSCLC Receiving Maintenance Therapy

Rittmeyer, A. (2015) · Cancers · doi:10.3390/cancers7020817 · Cited by 4

Bringing a genomic perspective to the safety of drug treatment in oncology

Innocenti, F. (2017) · F1000Research · doi:10.12688/f1000research.10475.1 · Cited by 4

Concordance between patient-reported and physician-reported sexual function after radical prostatectomy

Thong, A. E. C., Poon, B. Y., Lee, J. K., Vertosick, E., Sjoberg, D. D., Vickers, A. J., & Ehdaie, B. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.09.017 · Cited by 4

Factors affecting postmusculoskeletal tumour surgery wound problem treatment with negative pressure wound therapy

Baysal, Ö., Sağlam, F., Akgülle, A. H., Sofulu, Ö., Yiğit, O., Şirin, E., & Erol, B. (2020) · International Wound Journal · doi:10.1111/iwj.13326 · Cited by 4

Edmonton Symptom Assessment Scale may reduce medical visits in patients undergoing chemotherapy for breast cancer

Sanna, V., Fedele, P., Deiana, G., Alicicco, M. G., Ninniri, C., Santoro, A. N., Pazzola, A., & Fancellu, A. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i7.577 · Cited by 4

Oral Problems in Oncology Patients Undergoing Chemotherapy for Solid Tumors: A Prospective Observational Study

Ottaviani, G., Targato, G., Rupel, K., Gobbo, M., Generali, D., Guglielmi, A., Dicorato, A., Adamo, D., Canfora, F., Lenarda, R. D., et al. (2023) · Cancers · doi:10.3390/cancers16010176 · Cited by 4

Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2–negative breast cancer: A trajectory analysis of adverse events

Ip, E. H., Saldana, S. J., Miller, K. D., Carlos, R. C., Gareen, I. F., Sparano, J. A., Graham, N., Zhao, F., Lee, J., O'Connell, N. S., et al. (2021) · Cancer · doi:10.1002/cncr.33992 · Cited by 4

A comparison of nurses’ and physicians’ perception of cancer treatment burden based on reported adverse events

Lee, S. M., Miao, J., Wu, R., Unger, J. M., Cheung, K., & Hershman, D. L. (2019) · Health and Quality of Life Outcomes · doi:10.1186/s12955-019-1210-1 · Cited by 4

Public-private partnerships in transplant drug development

Albrecht, R., Papadopoulos, E. J., Campbell, M., Daniels, S. R., Kluetz, P. G., Parekh, A., & Wang, Y. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15604 · Cited by 4

Patient Reported Outcomes: Recent Successes and Future Opportunities

Melamed, A., & Wright, A. A. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.12.016 · Cited by 4

Promise of Patient-Reported Outcomes, Biometric Data, and Remote Monitoring for Adoptive Cellular Therapy

Kirtane, K., Jim, H., Gonzalez, B. D., & Oswald, L. B. (2022) · JCO Clinical Cancer Informatics · doi:10.1200/cci.22.00013 · Cited by 4

The Breaking Point and Post-Traumatic Growth in Breast Cancer Survivors

Franco, A., & Magno, S. (2023) · Cancers · doi:10.3390/cancers15184441 · Cited by 4

Concordance of patient- and clinician-reported outcomes of acute radiation dermatitis in breast cancer

Gojsevic, M., Rajeswaran, T., Zhang, L., Kennedy, S. K. F., Karam, I., Ding, K., Herst, P. M., Wong, H. C. Y., Kwan, J. Y. Y., Safavi, A. H., et al. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08966-6 · Cited by 3

Patient-Reported Outcome Measurement and Reporting for Patients with Soft Tissue Tumors: A Scoping Literature Review

Mazzocca, A., Paternostro, F., Garofalo, S., Silletta, M., Romandini, D., Orlando, S., Ambrogioni, L. R., Gorgone, P., Tonini, G., & Vincenzi, B. (2025) · Cancers · doi:10.3390/cancers17142280 · Cited by 3

Exploring Perspectives of Patients With Cancer on Implementing Electronic Patient-Reported Outcome Measures to Enhance Patient-Centered Care: Qualitative Study

Skåre, T. S., Lundeby, T., Lund, J., Lundereng, E. D., Kaasa, S., de Glas, N. A., Øyen, K. R., Guldhav, K. V., & Midtbust, M. H. (2025) · JMIR Cancer · doi:10.2196/79144 · Cited by 3

Development of a conceptual framework to detect perioperative symptom burden following abdominal surgery for cancer

Birgin, E., Müller, M., Woll-Weber, C. F. J., Klompmaker, A., Téoule, P., Reißfelder, C., & Rahbari, N. N. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.05.008 · Cited by 2

Assessment of Patient-Reported Outcomes in Industry-Sponsored Phase I Oncology Studies: Considerations for Translating Theory Into Practice

Gnanasakthy, A., Norcross, L., & Fitzgerald, K. A. (2023) · Value in Health · doi:10.1016/j.jval.2023.06.006 · Cited by 3

A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple Myeloma

Mian, H. S., Seow, H. Y., Balitsky, A. K., Cheung, M. C., Gayowsky, A., Tay, J., Wildes, T. M., McCurdy, A. B. R., Visram, A., Sandhu, I., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae041 · Cited by 3

Most Common Symptomatic Adverse Reactions of Cancer Treatments From US Drug Labels (2015-2021) to Inform Selection of Patient-Reported Outcomes

Horodniceanu, E. G., Datla, T., Murugappan, M. N., Kanapuru, B., Amiri‐Kordestani, L., Larkins, E. A., Kluetz, P. G., & Bhatnagar, V. (2024) · Value in Health · doi:10.1016/j.jval.2024.09.009 · Cited by 3

Prognostic impact of patient-reported symptoms in multiple myeloma

Abdallah, N. H., Bohra, A., Mammadzadeh, A., Buadi, F. K., Kapoor, P., Dispenzieri, A. A., Gertz, M. A., Hayman, S. R., Elhaj, M., Dingli, D., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014232 · Cited by 3

Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials

Miller, A. M., Passy, A. H., Sherry, A. D., Kouzy, R., Jaoude, J. A., Lin, T. A., Kupferman, G. S., Beck, E. J., Msaouel, P., & Ludmir, E. B. (2025) · JCO Oncology Practice · doi:10.1200/op-24-00735 · Cited by 3

Evaluation of the psychometric properties of patient-reported outcome measures of health-related quality of life across the European cancer continuum: a systematic review protocol using COSMIN methodology

Leysen, L., Giljevic, K. M., Piccinin, C., Shkodra, M., Pe, M. L., Petersen, M. A., Apolone, G., Brunelli, C., Lombardo, C., Velikova, G., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-088716 · Cited by 3

CDK4/6 Inhibitors in Patients with Breast Cancer: A Review of Adverse Event Profiles and Recommendations for Supportive Care Interventions

Post, K. E., Holtze, M., Isakoff, S. J., Ellisen, L. W., Jacobs, J. M., Wander, S. A., & Greer, J. A. (2025) · Current Breast Cancer Reports · doi:10.1007/s12609-025-00576-3 · Cited by 3

Big Data and Pharmacovigilance: The Role of Oncology Nurses

Glenn, D. G. (2016) · Clinical journal of oncology nursing · doi:10.1188/16.cjon.478-480 · Cited by 3

Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting

Rapoport, B. L., Gascón, P., Scotté, F., Jordan, K., Maïo, M. D., Börjeson, S., & Ahmedzai, S. H. (2017) · European Oncology & Haematology · doi:10.17925/eoh.2017.13.02.120 · Cited by 3

Functional “omics” for systems medicine

Villa, A., & Sonis, S. T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813762-8.00009-8 · Cited by 3

Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care)

Osawa, T., Fujii, Y., Kimura, G., Kitamura, H., Nagashima, Y., Iizumi, S., Osaka, T., Tsubouchi, R., & Shinohara, N. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-070275 · Cited by 5

Cancer therapy–related vaginal toxicity: its prevalence and assessment methods—a systematic review

Claes, M., Tuts, L., Robijns, J., Mulders, K., de Werf, E. V., Bulens, P., & Mebis, J. (2024) · Journal of Cancer Survivorship · doi:10.1007/s11764-024-01553-y · Cited by 3

ENABLE—App-Based Digital Capture and Intervention of Patient-Reported Quality of Life, Adverse Events, and Treatment Satisfaction in Breast Cancer: Protocol for a Randomized Controlled Trial

Deutsch, T. M., Volmer, L. L., Feißt, M., Bodenbeck, L., Haßdenteufel, K., Le, T. V., Breit, C., Stefanović, S., Bauer, A., Anders, C., et al. (2025) · JMIR Research Protocols · doi:10.2196/69855 · Cited by 5

Quality of life assessment and supportive management in a cancer outpatient setting in Saudi Arabia

Sadler, K., Abudari, G. A., Sweilem, A. S., Aldhari, M., & AlShammari, F. M. (2022) · Saudi Journal for Health Sciences · doi:10.4103/sjhs.sjhs_36_22 · Cited by 3

eHealth-Based Interventions for Older Patients with Prostate Cancer: A Quick Review of the Literature

Neto, L. S. S., Dias, F. C. F., Osório, N. B., & Rolim, C. L. A. (2022) · Telemedicine Reports · doi:10.1089/tmr.2021.0048 · Cited by 4

Communicating Treatment-Related Symptoms Using Passively Collected Data and Satisfaction/Loyalty Ratings: Exploratory Study

Kudel, I., & Perry, T. (2022) · JMIR Cancer · doi:10.2196/29292 · Cited by 2

A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)

Baek, S. K., Jeong, J.-H., Jung, K. H., Ahn, H. K., Kim, M. H., Sohn, J., Park, I. H., Ahn, J. S., Lee, D., Im, S., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231225029 · Cited by 2

Acceptability of an Electronic Patient-Reported Outcomes-Based Model of Care to Monitor Symptoms Related to Cancer Treatment with Immune Checkpoint Inhibitors: Results from the IePRO Randomized Controlled Trial

Lopes, A. M. D. S., Giacomini, S., Ulahannan, A., Darnac, C., Bugeia, S., Gutknecht, G., Colomer‐Lahiguera, S., Spurrier‐Bernard, G., Latifyan, S., Addeo, A., et al. (2025) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2025.151903 · Cited by 2

Einsatz von Patient-Reported Outcome Measures im Verlauf der Krebstherapie

Maïo, M. D. (2025) · Die Onkologie · doi:10.1007/s00761-025-01834-w · Cited by 2

Health‐related quality of life and symptom profile of patients with BCR::ABL1 ‐negative myeloproliferative neoplasms: Real‐world evidence from the GIMEMA‐PROPHECY observational study

Caocci, G., Costa, A. N., Palandri, F., Guglielmelli, P., Patriarca, A., Iurlo, A., Tieghi, A., Abruzzese, E., Baldi, T., Rossi, E., et al. (2025) · HemaSphere · doi:10.1002/hem3.70274 · Cited by 2

Sharing patient-reported outcomes with clinical investigators in real time

Basch, E., & Dueck, A. C. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00009-4 · Cited by 1

SNF-CLIMEDIN: A Randomized Trial of Digital Support and Intervention in Patients With Advanced Non–Small Cell Lung Cancer. A Hellenic Cooperative Oncology Group Study

Kosmidis, P., Kosmidis, T., Papadopoulou, K., Korfiatis, N., Vozikis, A., Lampaki, S., Economopoulou, P., Fountzilas, E., Christopoulou, A. N., Samantas, E., et al. (2026) · JCO Clinical Cancer Informatics · doi:10.1200/cci-25-00234 · Cited by 2

Post-radiotherapy health utility and symptom trends in patients with non-metastatic head and neck cancer

Larrotta-Castillo, D. A., Chen, Y. H., der Hoek, L. V., Ramaekers, B. L. T., Leeneman, B., Groot, C. A. U., Langendijk, J. A., & Blommestein, H. M. (2026) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2026.111473 · Cited by 2

Discrepancy between subjective and objective postoperative oral dysfunction assessment after oral cancer treatment: A single-center cross-sectional study

Kato, A., Matsuda, Y., Morioka, R., Okui, T., Okuma, S., Tatsumi, H., & Kanno, T. (2022) · Oral Oncology · doi:10.1016/j.oraloncology.2022.105879 · Cited by 2

Bloodletting therapy for primary headache: A systematic review and meta-analysis of randomized controlled trials

Dong, S., Wang, Y., Li, B., Liang, S.-B., & Cao, H. (2023) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2023.102312 · Cited by 3

Nutzung von elektronisch erfassten Patientenselbsteinschätzungen am Nationalen Centrum für Tumorerkrankungen Dresden

Eichler, M., Hentschel, L., Hornemann, B., Richter, S., Meier, F. E., Weitz, J., Schaser, K.-D., Krause, M., Thomas, C., Mütherig, A., et al. (2024) · Die Onkologie · doi:10.1007/s00761-024-01638-4 · Cited by 2

Comparison of patient-reported symptoms with multi-item patient-reported outcome measures of fatigue, anxiety, and depression in the clinical care of women undergoing chemotherapy for early breast cancer

Nyrop, K. A., Deal, A. M., Aman, C., Muss, H. B., & Reeve, B. B. (2025) · Quality of Life Research · doi:10.1007/s11136-025-03891-5 · Cited by 2

Performance Improvement of a Natural Language Processing Tool for Extracting Patient Narratives Related to Medical States From Japanese Pharmaceutical Care Records by Increasing the Amount of Training Data: Natural Language Processing Analysis and Validation Study

Ohno, Y., Aomori, T., Nishiyama, T., Kato, R., Fujiki, R., Ishikawa, H., Kiyomiya, K., Isawa, M., Mochizuki, M., Aramaki, E., et al. (2025) · JMIR Medical Informatics · doi:10.2196/68863 · Cited by 2

Real-Life Experience of HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Advanced Breast Cancer Patients Treated With T-DXd (Trastuzumab Deruxtecan): A Multicentric Portuguese Study

Bizarro, R., Pazos, I., Teixeira, A., Pereira, M., Gonçalves, J., Abreu, C., Ferreira, R. M., Oliveira, S. M. R., Mendes, A. D., Eiriz, I., et al. (2025) · Cureus · doi:10.7759/cureus.79734 · Cited by 2

Predictive and Prognostic Significance of Patient‐Reported Outcomes for Survival and Adverse Events in Daratumumab‐Treated Multiple Myeloma

Abuhelwa, A. Y., Almansour, S. A., Basch, E., Al-Shamsi, H. O., Abuhelwa, Z., Bustanji, Y. K., Semreen, M. H., Kharaba, Z. J., Ali, S. M., Mohamed, R., et al. (2025) · European Journal Of Haematology · doi:10.1111/ejh.14410 · Cited by 2

Esophagus-sparing radiotherapy for complicated spinal metastases (ESO-SPARE). A randomized phase III clinical trial

Nielsen, A. M., Laursen, M. R. T., Rechner, L. A., Krog, S. M., Storm, K. S., Ottosson, W., Gram, V. R., Suppli, M. H., Sibolt, P., Vogelius, I. R., et al. (2025) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2025.110906 · Cited by 2

Early detection of drug-induced interstitial lung disease using an electronic patient-reported outcome system: a report of two cases

Takei, Y., Matsumoto, A., Nomoto, A., Kawashima, M., Miyake, Y., Kawakami, A., Shima, T., Teshima, I., Nomoto, N., Mitsunaga, Y., et al. (2025) · International Cancer Conference Journal · doi:10.1007/s13691-025-00792-9 · Cited by 2

Validation of the Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator 17‐Item Symptom Index (FACT‐ICM‐17) to facilitate implementation in research and clinical care

Gudenkauf, L. M., Tometich, D. B., Hoogland, A. I., Li, X., Kirtane, K., Small, B. J., Barata, A., Gonzalez, B. D., Jacobs, K. D., Chung, C. H., et al. (2025) · Cancer · doi:10.1002/cncr.70102 · Cited by 2

Recurrence Score Testing Does not Appear to Benefit Patients With Grade 1, Progesterone Receptor-Positive Breast Cancers

Sibia, U. S., Sanders, T. J., Mylander, C. W., Rosman, M., Tweed, C. K., Tafra, L., & Jackson, R. S. (2021) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2021.05.005 · Cited by 2

A feasibility exploratory study of a novel modality of using patient-reported outcomes (PROsEXPLOR) in the real world

Grosso, F., Crivellari, S., Bertolotti, M., Lia, M., Angelis, A. D., Cassinari, A., Riccio, C., Piovano, P. L., Cappelletti, M., & Maconi, A. (2020) · Tumori Journal · doi:10.1177/0300891620923745 · Cited by 2

Construct and discriminant validity testing of the FACE‐Q Head and Neck Cancer Module for assessing speech and swallowing outcomes for patients undergoing maxillectomy or mandibulectomy

Venchiarutti, R. L., Charters, E. K., Dunn, M., & Clark, J. R. (2023) · Head & Neck · doi:10.1002/hed.27366 · Cited by 2

Electronic symptom monitoring for patients with advanced cancer

Liu, L., Wang, T., Chen, Y., & Cao, Y. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015732 · Cited by 2

Écarts d’évaluation entre oncologues, infirmiers et patients dans la prise en charge et l’impact des nausées et vomissements chimio/radio-induits : résultats français de l’enquête GAP

Morin, S., Leurs, I., Bousquet, M.-N., & Scotté, F. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2016.02.011 · Cited by 2

A Field Test of Major Value Frameworks in Chemotherapy of Nasopharyngeal Carcinoma—To Know, Then to Measure

Zhang, Y., Liu, X., Li, Y., Tang, L., Chen, L., & Ma, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01076 · Cited by 2

The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study

Kim, J. H., Seo, S., Kim, J. H., Koh, S., Ahn, Y., Jung, K. H., Ahn, J., Kim, S., Kim, T. W., Hong, Y. S., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4476 · Cited by 2

Some precautions about herbs.

Biron, C. R. (1999) · PubMed · Cited by 2

Faculty Opinions recommendation of Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.

Plaxe, S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732641164.793560786 · Cited by 2

Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit?

Mosele, F., & Maïo, M. D. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.011 · Cited by 2

Clinical relevance of reports on early access programs for checkpoint inhibitors in cancer patients: a French retrospective nationwide cohort study

Chatain, A., Fenioux, C., Lamé, G., Bouras, A., Babai, S., Ahmed, E. S., Monard, A., Manuceau, G., Tournigand, C., Albin, N., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103711 · Cited by 1

Exploration of Predictive Factors for Acute Radiotherapy-Induced Gastro-Intestinal Symptoms in Prostate Cancer Patients

Bruyn, P. D., Klass, M., Muylem, A. V., Jullian, N., Otte, F.-X., Diamand, R., & Preiser, J. (2025) · Cancers · doi:10.3390/cancers17244035 · Cited by 1

Application de la télésurveillance médicale à l’oncologie : référentiel AFSOS pour une prise en charge en 2025

Méglio, E. D., Basset, A., Hocine, M., Heudel, P., Seguin, L., Kempf, E., Boiteau, C., Carbasse, C., & Fiteni, F. (2025) · Bulletin du Cancer · doi:10.1016/j.bulcan.2025.09.007 · Cited by 1

Symptom Monitoring in Ovarian Cancer Patients Treated with PARP Inhibitors: Agreement Between Physician- and Patient-Reported Toxicities Using PRO-CTCAE

Massobrio, R., Attianese, D., Testi, A., Pascotto, M., Campigotto, B., Garulli, C., Pace, L., Ricotti, A., Fuso, L., & Ferrero, A. (2026) · Cancers · doi:10.3390/cancers18040650 · Cited by 1

Interactive symptom monitoring and coaching to optimise toxicity management of chemo(immune)therapy in early stage breast cancer: study protocol of the multicentre randomised controlled eChemoCoach trial

Verduin, R. J. T., van den Hurk, C. J. G., van Maurik, I. S., Nota, N. M., van Leeuwen‐Stok, A. E., Komen, M. M. C., Jager, A., Drossaert, C. H. C., Siesling, S., & Hendriks, M. P. (2026) · BMC Cancer · doi:10.1186/s12885-026-15905-7 · Cited by 1

SPINAL: study protocol for a multicenter non-inferiority trial evaluating reduce vertebral irradiation volumes in palliative radiotherapy for spinal bone metastases on analgesic efficacy

Faivre, J.-C., Lambert, A., Bruand, M., Francais, A., Supiot, S., Thureau, S., Bourbonne, V., Tomaszewski, F., Charra-Brunaud, C., Py, J.-F., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-16053-8 · Cited by 1

Symptoms experienced during the first 4 months of chemotherapy administration: a longitudinal cohort study in an Australian cancer treatment unit

Alexander, K. E., Ogle, T., Scanlon, B., Farley, M. J., Bradford, N., Pitt, E., Hoberg, H., Herron, E., Doyle, L., Abraham, R., et al. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-10955-w · Cited by 1

Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis

Caputo, R., Buono, G., Martinelli, C., Botticelli, A., Caltavituro, A., Pantano, F., Guarino, A., Bonomo, M. V., Diana, A., Carlino, F., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108251 · Cited by 1

Residual Platinum-Induced Neuropathy and the Feasibility of Second-Line Paclitaxel–Ramucirumab Therapy in Advanced Gastric Cancer: Prospective Multicenter Evidence from Japan

Nagasaka, T., Kono, Y., Kito, Y., Ando, T., Negoro, Y., Abe, T., Kuramochi, H., Boku, S., Mannami, T., Nasu, J., et al. (2026) · Cancers · doi:10.3390/cancers18142243 · Cited by 1

Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer

Karsten, M. M., Gebert, P., Pross, T., Hage, A. M., Dordevic, A. D., Stephan, S., Kühn, F., Doppelbauer, L., Blohmer, J., Fischer, F., et al. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2026.2661 · Cited by 1

Doctors less likely than patients to report toxicity of cancer treatments, study shows

Mayor, S. (2015) · BMJ · doi:10.1136/bmj.h485 · Cited by 1

Micellar paclitaxel in the treatment of patients with tumors of the female reproductive system

Кедрова, А. Г., Krasilnikov, S. E., Анатольевич, А. Д., & Kosyy, V. V. (2019) · Tumors of female reproductive system · doi:10.17650/1994-4098-2019-15-3-37-43 · Cited by 1

Symptomatic Toxicities Experienced During Anti-Cancer Treatment: Comparison of Patients' and Physicians' Reporting in Three Randomized Controlled Trials (Rcts)

Maïo, M. D., Piccirillo, M. C., Daniele, G., Nuzzo, F., Gridelli, C., Gebbia, V., Ciardiello, F., Placido, S. D., Ceribelli, A., Favaretto, A. G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu356.2 · Cited by 1

Doctors less likely than patients to report toxicity of cancer treatments, study shows

Mayor, S. (2015) · BMJ · doi:10.1136/bmj.h485 · Cited by 1

Under-reporting of subjective symptoms and its prognostic value. A pooled analysis of 12 cancer clinical trials.

Arenare, L., Liello, R. D., Placido, P. D., Gridelli, C., Morabito, A., Pignata, S., Nuzzo, F., Avallone, A., Maiello, E., Gargiulo, P., et al. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.8309691

Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)

Gravis, G., Marino, P., Joly, F., Oudard, S. M., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.034 · Cited by 69

Patient-reported outcomes in the evaluation of toxicity of anticancer treatments

Perrone, F., Basch, E., Bryce, J., & Maïo, M. D. (2022) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/sc1k-1404